Since BC therapy commonly involves drugs that target ER, PR and HER2 expressed by HR-positive and HER2-positive breast cancer cells, the absence of these receptors makes treatment of TNBC challenging and associated with treatment failure and disease recurrence [2,14]. This evidence concerns the gene ESR1 and breast carcinoma.